Nemonoxacin: First Global Approval

Overview

Journal Drugs

Specialty Pharmacology

Date 2014 Aug 1

PMID 25079302

Citations 13

Authors

Raewyn M Poole

Affiliations

Soon will be listed here.

Abstract

Nemonoxacin (Taigexyn(®)), a non-fluorinated quinolone antibacterial agent, is under development with TaiGen Biotechnology for the oral and intravenous treatment of community-acquired pneumonia (CAP) and the oral treatment of diabetic foot ulcer infections and skin and soft tissue infections. Oral nemonoxacin has been approved in Taiwan for the treatment of CAP in adults. This article summarizes the milestones in the development of nemonoxacin leading to this first approval for the treatment of CAP.

Citing Articles

Potential effectiveness of parenteral nemonoxacin in the treatment of infections: , , and mouse studies.

Lee C, Yan X, Wu H, Ko W, Tsai P, Hung Y Front Microbiol. 2024; 15:1418817.

PMID: 39228379 PMC: 11368742. DOI: 10.3389/fmicb.2024.1418817.

Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile?.

Rusu A, Munteanu A, Arbanasi E, Uivarosi V Pharmaceutics. 2023; 15(3).

PMID: 36986665 PMC: 10056716. DOI: 10.3390/pharmaceutics15030804.

Asymmetric Synthesis of US-FDA Approved Drugs over Five Years (2016-2020): A Recapitulation of Chirality.

Tamatam R, Shin D Pharmaceuticals (Basel). 2023; 16(3).

PMID: 36986439 PMC: 10052577. DOI: 10.3390/ph16030339.

Safety of oral nemonoxacin: A systematic review of clinical trials and postmarketing surveillance.

Yuan J, Zhang X, Chen J, Zhang Y, Zhu F, Huang H Front Pharmacol. 2022; 13:1067686.

PMID: 36569296 PMC: 9780658. DOI: 10.3389/fphar.2022.1067686.

Fluoroquinolones Hybrid Molecules as Promising Antibacterial Agents in the Fight against Antibacterial Resistance.

Lungu I, Moldovan O, Biris V, Rusu A Pharmaceutics. 2022; 14(8).

PMID: 36015376 PMC: 9414178. DOI: 10.3390/pharmaceutics14081749.

References

Liao C, Ko W, Lu J, Hsueh P . Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan. Antimicrob Agents Chemother. 2012; 56(7):3943-9. PMC: 3393409. DOI: 10.1128/AAC.00191-12. View

Adam H, Laing N, King C, Lulashnyk B, Hoban D, Zhanel G . In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. Antimicrob Agents Chemother. 2009; 53(11):4915-20. PMC: 2772340. DOI: 10.1128/AAC.00078-09. View

Lai C, Lee K, Lin S, Chen Y, Kuo H, Hung C . Nemonoxacin (TG-873870) for treatment of community-acquired pneumonia. Expert Rev Anti Infect Ther. 2014; 12(4):401-17. DOI: 10.1586/14787210.2014.894881. View

Peto L, Nadjm B, Horby P, Ngan T, van Doorn R, Van Kinh N . The bacterial aetiology of adult community-acquired pneumonia in Asia: a systematic review. Trans R Soc Trop Med Hyg. 2014; 108(6):326-37. PMC: 4023908. DOI: 10.1093/trstmh/tru058. View

Li C, Li Y, Li G, Yang X, Zhang W, Lou R . In vivo antibacterial activity of nemonoxacin, a novel non-fluorinated quinolone. J Antimicrob Chemother. 2010; 65(11):2411-5. DOI: 10.1093/jac/dkq341. View

Lin Y, Huang Y, Tsai P, Lee T, Lee N, Liao C . Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in taiwan. Antimicrob Agents Chemother. 2011; 55(4):1701-5. PMC: 3067156. DOI: 10.1128/AAC.01440-10. View

Lai C, Liu W, Ko W, Chen Y, Tan H, Huang Y . Multicenter study in Taiwan of the in vitro activities of nemonoxacin, tigecycline, doripenem, and other antimicrobial agents against clinical isolates of various Nocardia species. Antimicrob Agents Chemother. 2011; 55(5):2084-91. PMC: 3088233. DOI: 10.1128/AAC.01808-10. View

Lauderdale T, Shiau Y, Lai J, Chen H, King C . Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. Antimicrob Agents Chemother. 2010; 54(3):1338-42. PMC: 2825994. DOI: 10.1128/AAC.01197-09. View

Chotikanatis K, Kohlhoff S, Hammerschlag M . In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother. 2013; 58(3):1800-1. PMC: 3957896. DOI: 10.1128/AAC.02263-13. View

10.

Liang W, Chen Y, Cao Y, Liu X, Huang J, Hu J . Pharmacokinetics and pharmacodynamics of nemonoxacin against Streptococcus pneumoniae in an in vitro infection model. Antimicrob Agents Chemother. 2013; 57(7):2942-7. PMC: 3697386. DOI: 10.1128/AAC.01098-12. View

11.

van Rensburg D, Perng R, Mitha I, Bester A, Kasumba J, Wu R . Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia. Antimicrob Agents Chemother. 2010; 54(10):4098-106. PMC: 2944601. DOI: 10.1128/AAC.00295-10. View

12.

Song J, Thamlikitkul V, Hsueh P . Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region. Int J Antimicrob Agents. 2011; 38(2):108-17. DOI: 10.1016/j.ijantimicag.2011.02.017. View

13.

Goyet S, Vlieghe E, Kumar V, Newell S, Moore C, Bousfield R . Etiologies and resistance profiles of bacterial community-acquired pneumonia in Cambodian and neighboring countries' health care settings: a systematic review (1995 to 2012). PLoS One. 2014; 9(3):e89637. PMC: 3953073. DOI: 10.1371/journal.pone.0089637. View

14.

Chung D, Tsai C, Chen S, Chang L, King C, Hsu C . Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. Antimicrob Agents Chemother. 2009; 54(1):411-7. PMC: 2798523. DOI: 10.1128/AAC.00683-09. View

15.

Torres A, Blasi F, Peetermans W, Viegi G, Welte T . The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. Eur J Clin Microbiol Infect Dis. 2014; 33(7):1065-79. PMC: 4042014. DOI: 10.1007/s10096-014-2067-1. View

16.

Mandell L, Wunderink R, Anzueto A, Bartlett J, Campbell G, Dean N . Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44 Suppl 2:S27-72. PMC: 7107997. DOI: 10.1086/511159. View

17.

Bush K . Improving known classes of antibiotics: an optimistic approach for the future. Curr Opin Pharmacol. 2012; 12(5):527-34. DOI: 10.1016/j.coph.2012.06.003. View

18.

Tan C, Lai C, Liao C, Chou C, Hsu H, Huang Y . Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother. 2009; 64(2):428-9. DOI: 10.1093/jac/dkp174. View

19.

Lai C, Tan C, Lin S, Liao C, Chou C, Hsu H . Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species. J Antimicrob Chemother. 2009; 64(1):73-8. DOI: 10.1093/jac/dkp144. View

20.

Guo B, Wu X, Zhang Y, Shi Y, Yu J, Cao G . Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses. Clin Drug Investig. 2012; 32(7):475-86. DOI: 10.2165/11632780-000000000-00000. View